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Introduction
It is estimated that 5% of critically ill patients with acute
kidney injury (AKI) require renal replacement therapy
(RRT). Increasing data suggests that they have an
increased risk of progressive chronic kidney disease, car-
diovascular morbidity and premature death. The exact
reasons for these poor outcomes following AKI are
incompletely understood. Discontinuation of cardiopro-
tective drugs may be an important factor.
Objectives
To describe the influence of AKI requiring RRT on long
term cardioprotective drug prescription in survivors to
hospital discharge during a two year period.
Methods
We identified all patients who received RRT for AKI in
a large tertiary Intensive Care Unit (ICU) over a two
year period. For those who recovered to RRT indepen-
dence and survived to hospital discharge, documentation
at admission and discharge from ICU and the hospital
were reviewed to assess changes to medications and the
information conveyed to primary care. We focussed on
the following drugs: Metformin, renin-angiotensin-
system blockers, beta-blockers, K sparing diuretics, statins
and antiplatelet agents. Where patients were repatriated to
other hospitals letters were sent to the general practitioners.
Results
Full data was available for 130/178 patients (75%). Of 88
patients treated with at least one of the medications of
interest 53 (60.2%) had at least one drug discontinued.
(Table 1) Information regarding the AKI episode and
the discontinued drugs were appropriately documented
in the hospital discharge letters in only half of these.
Conclusions
1. It was common for patients with AKI to be prescribed
cardioprotective drugs at the time of admission and for
some or all to be discontinued during critical illness.
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regarding AKI and drug
discontinuation (% of relevant
patients)
V 3 (2.3%) 2 >60 (2 pts) 12 2 (100%) 2 (100%)
IV 18 (13.8%) 14 38.9 (9 pts) 24.1 9 (64%) 5 (55.5%)
IIIb 28 (21.5%) 25 59.4 (21 pts) 39 17 (68%) 12 (71%)
IIIa 24 (18%) 15 44.1 (7 pts) 52.4 8 (53%) 3 (38%)
I or II 58 (44.6%) 32 >60 (22 pts) >60 17 (53%) 8 (47%)
Total 130 88 61 pts 88 pts 53 (60.2%) 30 (56.6%)
Abbreviations: AKI = acute kidney injury; eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease.
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Many patients recovered a good level of renal function by
hospital discharge but still had medications discontinued.
Whilst it may have been appropriate during the acute ill-
ness, prolonged discontinuation may have had an effect
on the stability of co-morbid disease in the longer term.
2. Although primary care physicians are increasingly
responsible for management of chronic conditions and
rely upon accurate and complete information from sec-
ondary care, the transfer of relevant information related
to medication management was frequently sub-optimal
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